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Expedited growth factor-mediated specification
of human embryonic stem cells toward the
hepatic lineage
Rebecca N. Moorea, Prabhas V. Moghea,b,⁎a Department of Biomedical Engineering, Rutgers University, 599 Taylor Road, Piscataway, NJ 08854, USA
b Department of Chemical and Biochemical Engineering, Rutgers University, 599 Taylor Road, Piscataway, NJ 08854, USAReceived 13 September 2008; received in revised form 27 February 2009; accepted 29 April 2009Abstract Human embryonic stem cells (hESCs) have the potential to be a promising source of liver cells, hepatocytes, for
regenerative medicine given their unlimited proliferative and pluripotent differentiative capacity. However, the inefficient
embryoid body process and limited understanding of molecular signals potentiating cell-specific differentiation plague the use
of hESCs as a hepatic source. In this study, we describe an efficient growth factor-based process for directed differentiation of
hESCs that bypasses embryoid body development. The system involves adherent hESC culture exposure to activin A treatment
followed by incorporation of various growth factor combinations composed of dexamethasone, oncostatin M, hepatocyte
growth factor, and Wnt3A. The hESC-derived hepatocyte-like cells resulting from optimal growth factor combinations exhibit
characteristic hepatocyte morphology, express hepatocyte markers, and possess hepatospecific functional activity. The
differentiated cultures express hepatic-related genes shown by reverse transcription–polymerase chain reaction and
immunofluorescence analysis revealed binucleated cells with coexpression of albumin/cytokeratin 18. Furthermore, the
hESC-derived hepatocyte-like cells exhibit functional hepatic characteristics, such as indocyanine green uptake and release,
albumin secretion, and inducible cytochrome P450 activity. This directed differentiation of adherent hESCs offers an efficient
process to produce hepatocyte-like cells in vitro for hepatocyte differentiation studies and organotypic cultures for diagnostic
and therapeutic applications.
© 2009 Elsevier B.V. All rights reserved.Introduction
The field of stem cell bioengineering can potentially
revolutionize cell-based therapies for functional replace-
ment of metabolically complex tissues like that of the liver
(McKay, 2000; Mitaka, 2002; Miyashita et al., 2002; Daley,
2002; Fair et al., 2003). Significant challenges notwithstand-
ing, human embryonic stem cells (hESCs) offer a promising
cell source for transplantation medicine, particularly with⁎ Corresponding author. Fax: +1 732 445 3753.
E-mail address: moghe@rci.rutgers.edu (P.V. Moghe).
1873-5061/$ – see front matter © 2009 Elsevier B.V. All rights reserved
doi:10.1016/j.scr.2009.04.004the active efforts underway to guide embryonic stem (ES)
cell development and maturation (Choi et al., 2002; Hu et
al., 2004; Shirahashi et al., 2004). The ES cell model was
recently demonstrated to be highly organotypic based on its
successful realization of specific lineages (Kubo et al.,
2004a); however, molecular signals that can effectively
promote the integration and hepatospecific differentiation
of ESCs are only now beginning to be clarified (Selden and
Hodgson, 2004; Strain and Neuberger, 2002).
The ability of healthy human liver to regenerate is
steadily lost in chronic liver disease. The standard treatment
for advanced liver disease, which is the eighth leading cause.
52 R.N. Moore, P.V. Mogheof adult deaths globally, has been orthotopic liver organ
transplantation, but this therapy is limited by the availability
of donor tissue (Harper and Rosendale, 1996; Susick et al.,
2001). Cell transplantation of liver parenchymal cells,
hepatocytes, was shown to be an effective strategy in
animal models of hepatic failure and metabolic liver diseases
(Kobayashi et al., 2000; Strom et al., 1999); hepatocyte
transplantation has also been shown to be a plausible
treatment in human metabolic liver disease (Malhi and
Gupta, 2001; Fox et al., 1998). Hepatocyte engineering
continues to be an active field of investigation that has
brought the key issues of cell sourcing and organoid
definition to the forefront of the field of tissue engineering
(Griffith and Naughton, 2002; Allen and Bhatia, 2002). In
addition to hepatocyte-based therapies, hepatocyte cultures
are widely considered as diagnostic in vitro models for
preclinical functional and toxicogenomic screening of phar-
maceutical drugs (Harries et al., 2001; Modriansky et al.,
2000). However, the utility of hepatocytes in either clinical
or pharmaceutical applications is limited by their availability
and variability, as well as their limited proliferation and
decline in hepatic functions on extended in vitro cultures.
Embryonic stem cells afford a promising source of
hepatocytes given their unlimited proliferative and pluripo-
tent differentiative capacity (Hu et al., 2004; Chinzei et al.,
2002; Jochheim et al., 2004; Kania et al., 2004). Human
embryonic stem cells are derived, mechanically or immuno-
surgically, from the polarized inner cell mass of a preim-
plantation-stage blastocyst (Reubinoff et al., 2000; Thomson
et al., 1998). Spontaneous differentiation of hES colonies
rapidly occurs in vitro when the system lacks preventative
factors, such as basic fibroblast growth factor (bFGF). In two-
dimensional systems, spontaneous differentiation occurs at
the outer borders of the colonies, at fusing colonies, or at the
center core where cells begin to pile up (Sathananthan et al.,
2002). A three-dimensional culture system, in the form of
embryoid bodies, is another way to initiate differentiation of
hES cells (Itskovitz-Eldor et al., 2000). The appearance of all
three germ layers is possible in this suspension culture
system. Selecting specific cell-type populations can be
achieved with cell-surface markers and separation techni-
ques, although these procedures remain difficult to scale-up
and inefficient (Levenberg et al., 2002). The process of
directed differentiation is defined by induction into a
specific cell type, without the presence of all three germ
layers and can be enhanced by endogenous transcription
factor activation, transcription factor transfection, growth
factor supplements, or coculture environments (Pera and
Trounson, 2004; Trounson, 2005).
Endodermal differentiation from hESCs remains a chal-
lenge due to an incomplete understanding of the differentia-
tion process; therefore several investigators have utilized
complex processes to induce hepatic-like differentiation of
hESCs in both two- and three-dimensional culture systems in
vitro. A few successful approaches have supplemented
traditional embryoid body development by growth factor
treatment and the use of collagen scaffold systems (Bahar-
vand et al., 2006) or were enriched by reporter gene
purification by a hepatocyte-specific promoter to differenti-
ate hESCs (Lavon et al., 2004). Treatments incorporating
dimethyl sulfoxide and sodium butyrate have induced
hepatocyte markers in two-dimensional cultures of hESCs(Rambhatla et al., 2003). Baharvand and Shahsavan have
proposed an interesting 28-day method that utilizes a
multistep protocol of growth factors to mediate hepato-
cyte-like differentiation without the use of embryoid bodies
or serum (Baharvand et al., 2008). Similarly, Cai et al.
created hepatic cells from undifferentiated hESCs through a
18-day three-stage method in serum-free medium (Cai et al.,
2007). Activin A, sodium butyrate, dimethyl sulfoxide, and
oncostatin M were utilized to induce a differentiation
process that takes up to 3 weeks to differentiate hESCs
into hepatocyte-like cells (Hay et al., 2008a). Recently, Hay
et al. used activin A and Wnt3a to prime hESCs to induce
hepatocellular function in vitro and in vivo (Hay et al.,
2008b). Various groups have used a plethora of growth
factors and extracellular matrixes to induce hESC hepatic
differentiation (Ishii et al., 2008; Agarwal et al., 2008). Each
of these systems takes several days or weeks to differentiate
the hESCs, but the challenge still remains to create a direct
and efficient process for directed hepatic differentiation.
Largely inspired by the in vivo progression of hepato-
trophic stimuli during development (Duncan, 2000, 2003),
there have been extensive studies of molecular growth
factors that can interact with developing liver cells, fetal
liver cells, and, more recently, embryonic stem cells
(Shirahashi et al., 2004; Rambhatla et al., 2003; Rossi et
al., 2001; Michalopoulos et al., 2003; Dasgupta et al., 2005;
Levenberg et al., 2003; Schwartz et al., 2005). A complex
sequence of hepatotrophic factors has been implicated in the
process of liver development (Zaret, 2001). The interaction
between the endoderm and cardiac-mesoderm is crucial for
hepatic development (Cascio and Zaret, 1991). This process
results in the expression of two major liver-specific markers
alpha-fetoprotein (AFP) and albumin (ALB), which can be
detected as early as embryonic Days 8–9 (E8–E9). Hepatic
cells at this point can differentiate into parenchymal
hepatocytes or bile duct epithelial cells. At E10–11,
hematopoietic stem cells originating from the extrahepatic
organ colonize the fetal liver region and proliferate: hepatic
progenitors participate in creating a conducive hematopoie-
tic microenvironment (Mukouyama et al., 1998); in parallel,
hematopoietic cells produce cytokines, especially oncostatin
M (OSM), (Kamiya et al., 2001) while mesenchymal cells
(nonparenchymal liver cells) produce the hepatocyte growth
factor (HGF) (Kamiya et al., 1998), a mitogen and morpho-
gen, one of the key signals for liver development and
regeneration (Huh et al., 2004). The cooperative nature of
signals required for hepatic maturation is best exemplified
by the role played by growth factors secreted from
hematopoietic cells. The most significant of these include
dexamethasone (DEX) and oncostatin M (Kamiya et al., 2001,
1998; Kinoshita and Miyajima, 2002; Kojima et al., 2000).
DEX is known to suppress AFP production (early hepatic
marker) and DNA synthesis, while upregulating albumin (mid-
hepatic marker) and alpha-1-antitrypsin (AAT, late hepatic
marker) production. OSM, an interleukin (IL) 6 family
cytokine, has been shown to upregulate AAT and HNF-4.
The synergistic action of DEX and OSM has been found to
specifically induce hepatic maturation in fetal liver E14.5
(Kamiya et al., 2001, 1998) through induction of morpholo-
gical changes and upregulation of multiple liver-specific
functions (Kinoshita and Miyajima, 2002; Matsui et al., 2002).
Activin A reacts through the activin/nodal signaling pathway
Figure 1 Schematic illustrating human embryonic stem cell (hESC) culturing and the steps initiating differentiation. (A)
Undifferentiated hESCs were cultured on mitotically inactivated mouse embryonic fibroblasts. Following weekly passaging,
differentiation is initiated by the spontaneous differentiation method of embryoid body development or the expedited process of
growth factor supplementation in adherent culture. (B) The optimal media supplementation was selected from the table of growth
factors.
53Expedited growth factor-mediated specification of human embryonic stem cells toward the hepatic lineageand has been shown to induce definite endoderm differ-
entiation (McLean et al., 2007). The Wnt/beta-catenin
signaling cascade is involved in the hepatic differentiation
pathway and has been shown to induce hepatic endoderm by
Wnt3A treatment (Fletcher et al., 2008).
Although there is significant promise in the potential use
of the above maturation factors for ES cell differentiation,
the exclusive application of these factors leads to a
differentiation process that is inefficient and uncontrolled,
thus, an integrated and phased application of these factors
based on the complex cross-functional signaling pathways
may be necessary. The central premise of this study is that
optimal exogenous growth factor presentation to the
adherent hESCs during development can be used to
controllably expedite the process of directed differentiation
into the hepatic lineage, bypassing the use of poorly defined
embryoid body development (see Fig. 1).Results
Early hepatic-like differentiation in growth factor
supplemented cocktail
Previous studies in our laboratory have shown that the
optimal growth factor cocktail for mouse ES hepatocyte-like
differentiation is composed of the combination of DEX, OSM,and HGF (DOH) (Dasgupta et al., 2005). Therefore, we
examined the effects of DOH on the differentiative ability in
adherent hESCs. As shown in Fig. 2, there was pronounced
AFP expression after 1 week in culture on MEFs in the
presence of DOH media, whereas the H1 colony in complete
media lacking DOH supplementation only had stage-specific
embryonic antigen-4 (SSEA-4) staining, indicating prolifera-
tive abilities. After 2 weeks in culture, AFP was still present,
though not as prominent, and had achieved cells with a
larger cytoplasm to nuclear ratio. Our data indicate that
early hepatic-like differentiation is achieved when the
adherent cultures are presented with DOH supplementation.
This suggests that DOH is an effective growth factor
treatment for early differentiation of hESCs.Time course of genetic expression of hepatospecific
maturation markers in hESCs
Additional media supplementations were added to the DOH
treatment in an effort to further differentiate the hESCs in
adherent cultures. Activin A and Wnt3A were added in
various combinations to DOH treatment and evaluated for
hepatic differentiation over a 2-week time course. An A
(activin A, ActA) placed after DOH indicated the presence of
activin A throughout culture while an A placed before DOH
denotes a priori activin A treatment for 4 days and removal,
Figure 2 Early hepatic differentiation of hESCs grown on MEFs in the presence of DOH. Immunocytochemistry shows a prominent
expression of AFP in the adherent culture system supplemented with dexamethasone, oncostatin M, and hepatocyte growth factor
(DOH) after 1 week in culture. AFP expression is downregulated after 2 weeks in culture and cells are enlarged. Cultures grown in
complete and basal media show no AFP staining and pluripotency by SSEA-4 staining. Also shown are transmitted light images and
antibody isotype controls. Abbreviations: AFP, alpha-fetoprotein; SSEA-4, stage-specific embryonic antigen-4.
54 R.N. Moore, P.V. Moghefollowed by culture in the presence of the remaining growth
factors. Real-time reverse transcriptase-polymerase chain
reaction (RT-PCR) for an early (AFP) and mid (ALB) hepatic
marker was normalized to beta-actin mRNA levels and
evaluated for levels compared to basal media (Fig. 3). AFP
levels were higher after 1 week compared to 2 weeks,
indicating an increase in differentiation associated with AFP
levels diminishing. Albumin levels were enhanced after 2
weeks in culture compared to 1 week, indicating increased
differentiation in all growth factor combinations. For each
data set, the treatments that started with activin A
treatment (Ad0-4DOH and Ad0-4DOHW) showed high levels of
differentiation compared to basal media.
Endoderm and hepatic-specific gene expression of
high performers
The mRNA expression of endodermal and hepatocyte-
specific genes, such as forkhead box A2 (FOXA2), transthyr-
etin (TTR), alpha-1-antitrypsin (AAT), hepatocyte nuclear
factor-4 (HNF-4) and cytokeratin 18 (CK18) was observed in
the DOH, Ad0-4DOH, and Ad0-4DOHW cultures during differ-
entiation (Fig. 4). Complete media showed downregulation
of each marker, indicating suppression of hepatic differ-
entiation. Additionally, as a comparison for spontaneous
differentiation, the basal endodermal differentiation during
the formation of embryoid bodies (EB) was evaluated for
expression of each hepatic marker. FOXA2 and TTR were
upregulated, indicating endodermal differentiation, but
were downregulated for the hepatocyte-specific genes,AAT, HNF-4, and CK18. These results indicate that the high-
performance media induce hepatic differentiation of hESCs
in comparison to basal EB development, which produces
limited endoderm differentiation in the absence of supple-
mentation with exogenous growth factors.
hESC-derived hepatic cells exhibit hepatocyte-like
functions
Each growth factor combination from Fig. 3 was evaluated
for functional activity by albumin secretion for up to 2 weeks
in adherent culture (Fig. 5A). Albumin production continu-
ously increased and reached maximal values at day 14 with
the exogenous growth factor supplementation, Ad0-4DOH,
resulting in the highest level of albumin secretion. Statisti-
cally significant albumin production, compared to basal
media for the same day, was achieved by high-performance
media, DOH, Ad0-4DOHW, and Ad0-4DOH, and was further
investigated for late hepatic markers. These levels are on the
same order of magnitude as hepatocarcinoma Hep G2 cells
(Leclerc et al., 2004), indicating that efficient hepatic
differentiation is being achieved after only 14 days in
adherent culture.
Hepatic metabolism was evaluated using an ethoxyresor-
ufin O-de-ethylase (EROD) assay (Fig. 5B). The hESC-derived
hepatocyte-like cells were evaluated for inducible CYP1A2
activity since cytochrome P450 isoenzyme expression is
indicative of hepatocellular function (Ek et al., 2007). The
data illustrate that CYP1A2 activity was elevated in all high-
performance media (DOH, Ad0-4DOH, and Ad0-4DOHW) and
Figure 3 Progressive alteration of hESC hepatic differentia-
tion in growth factor combinations by reverse transcription–
polymerase chain reaction (RT-PCR). Levels of mRNA expression
were normalized to beta-actin and fold change was determined
from basal media. Data were analyzed in triplicate and displayed
as mean±SEM. EB and MEF conditions were grown in basal
media. (⁎ denotes Pb0.05 compared to EB mRNA levels.)
Abbreviations: AFP, alpha-fetoprotein; ALB, albumin; D, dex-
amethasone; O, oncostatin M; H, hepatocyte growth factor; A,
activin A; Ad0-4, activin A treatment only on Days 0-4; W, Wnt3a;
MEF, mouse embryonic fibroblast.
55Expedited growth factor-mediated specification of human embryonic stem cells toward the hepatic lineagebarely detectable in the control, complete media, indicating
that hESC-derived cells have the functional features of
hepatocytes.
To confirm liver-like metabolic function, ICG uptake and
release were evaluated for basal and high-performance
media after 2 weeks in culture (Fig. 5C). Uptake and release
of ICG may be used to identify hepatocytes in ES cell
differentiation models (Yamada et al., 2002). The images
show ICG uptake and release 6 h later in DOH, Ad0-4DOH, and
Ad0-4DOHW cultures. In contrast, the basal media did not
have the capacity to take up ICG and release it later. The
most pronounced uptake was achieved by DOH and Ad0-4DOH
cultures, indicating that hESC-derived hepatic cells have the
metabolic function to rapidly uptake and excrete ICG.Expression of hepatocyte markers in
hESC-differentiated cells
To evaluate the hepatic differentiation of hESCs in the high-
performance media, we costained for hepatic markers,
albumin and cytokeratin 18, for differentiation (Fig. 6).
The control, complete and basal media, resulted in negative
ALB/CK18 staining, but DOH, Ad0-4DOH, and Ad0-4DOHWresulted in elevated levels of ALB/CK18. The highest level
of ALB/CK18 was achieved in Ad0-4DOH media supplementa-
tion and displayed distinctively differentiated morphology,
such as the emergence of binucleated cells and character-
istic cuboidal phenotype.
To determine the percentage of cells expressing albumin
and cytokeratin 18 throughout 4 weeks of culture, flow
cytometry was utilized (supplemental data). Undifferen-
tiated cells expressed no albumin and CK18 expression. At
week 2, albumin (7.02%) begins to rise while CK18 (48.38%) is
greatly upregulated. For long-term, terminal differentiation
culture, at 4 weeks, 72.8% of cells are albumin positive and
72.9% are cytokeratin 18 positive. Therefore, Ad0-4DOH
media supplementation is an efficient protocol to induce
hepatic expression on a large population of cells.Discussion
Methods to differentiate hESCs into hepatocytes must be
direct, rapid, and offer high yields, in order to be widely
useful for basic research and therapeutic applications. Here
we describe an efficient protocol for exogenous growth
factor stimulation to induce hepatocyte-like cells from hESCs
without the use of embryoid bodies. Priming hESCs with
activin A to induce endodermal differentiation followed by
treatment with select growth factors that recapitulate
hepatogenesis in vivo results in cells with characteristic
hepatocyte morphology and that express hepatocyte mar-
kers and possess hepatospecific functional activity.
Pluripotent hESCs are preserved under very strict lab
practices, usually in culture with embryonic or adult somatic
cells that secrete products to maintain pluripotency.
Traditionally, hESCs are cocultured with mitotically inacti-
vated murine embryonic fibroblasts (MEFs) to form two-
dimensional colonies that must be maintained on a weekly
basis and supplemented with basic fibroblast growth factor
and TGF-β to help maintain self-renewal (Sato et al., 2004).
When these factors are removed from the culture and
maintained under appropriate conditions, hESCs can differ-
entiate into the three embryonic germ layers. To induce
differentiation, researchers have taken advantage of embry-
oid body development to mimic the environment of the peri-
implantation embryo to force lineage restriction (Wang et al.,
2008). Traditional hepatic terminal differentiation results
from progenitor cells isolated from the endoderm followed by
exposure to the proper molecular cues. This entire process
may take up to 28 days to derive EBs, subculture the
endoderm, and culture with growth factors (Baharvand et
al., 2006). If the complex embryoid body process is bypassed,
suitable growth factors will be necessary to recapitulate cues
for differentiation into hepatocyte-like cells.
In our study, growth factor components for media
supplementation were selected based on their published
abilities to induce hepatic differentiation in embryonic stem
cells. The initial growth factor selection for hepatic
differentiation of hESCs stemmed from our previous work
with mouse ES cells, concluding that the synergistic effects
of dexamethasone, oncostatin M, and hepatocyte growth
factor were optimal conditions for differentiation (Dasgupta
et al., 2005). Dexamethasone is a synthetic glucocorticoid
involved in liver gluconeogenesis (Lavon and Benvenisty,
Figure 4 Real-time RT-PCR analysis of liver-specific gene expression by hESC-derived cells after 2 weeks in culture in the high-
performance media. The mRNA expression of FOXA2 (A), TTR (B), AAT (C), HNF-4 (D), and CK 18 (E) shows elevated hepatic markers in
DOH, ADOH, and ADOHW cocktails and downregulation in complete media. Embryoid bodies (EB) show elevated expression in the
endodermal markers, FOXA2 and TTR, but downregulations in the late hepatic markers, AAT, HNF-4, and CK 18. Levels of mRNA
expression were normalized to beta-actin and fold change was determined from basal media. Data were analyzed in triplicate and
displayed as mean±SEM. (⁎ denotes Pb0.05 compared to EB, § denotes Pb0.01 compared to EB.) Abbreviations: FOXA2, forkhead box
A2; TTR, transthryretin; AAT, alpha-1-antitrypsin; HNF-4 hepatocyte nuclear factor-4; CK18, cytokeratin 18.
56 R.N. Moore, P.V. Moghe2005), oncostatin M induces fetal hepatocyte maturation
through the gp130 signal transducer (Kamiya et al., 1999),
and hepatocyte growth factor supports hepatogenesis by
activating the c-Jun pathways (Hay et al., 2007). Our data
suggest that the DOH combination is sufficient to induce a
hepatic response from hESCs within a very short period of
time. We then chose to investigate the addition of additional
growth factors, activin A and Wnt3A, to further direct
differentiation associated with DOH stimulation.
Activin A has been previously shown to restrict visceral
endoderm (Yasunaga et al., 2005), induce definitive endo-
derm differentiation from hESCs (Jiang et al., 2007; D'Amour
et al., 2005; Kubo et al., 2004b; Chen et al., 2006), and was
therefore assessed for incorporation with DOH treatments.Pretreatment with activin A for 4 days (Ad0-4DOH, Ad0-4DOHW)
was compared to constant activin A throughout the experi-
ment (DOHA, DOHAW). Molecular analysis showed that the
effects of basal DOH treatment could be improved on with
the addition of activin A pretreatment, indicating that the
hESCs are differentiating through a loss in AFP expression and
that activin A induces the highest levels of early hepatic
differentiation. This result is consistent with previous
observations of hESC liver development in which the initial
activin A treatment is an efficient signal to induce definitive
endoderm differentiation. Additionally, Wnt3a was investi-
gated for incorporation with DOH because of its known ability
to induce hepatic endoderm (Fletcher et al., 2008) and
Wnt3a expression has been demonstrated during human liver
Figure 5 Functional activity of hESC-derived hepatic-like cells. (A) Human albumin ELISA analysis of growth factor combinations. All
albumin concentrations were increased during differentiation with three growth factor combinations resulting in significantly more
albumin when compared to basal media for the same day. These results indicated that DOH, Ad0-4DOHW, and Ad0-4DOH result in the
greatest level of differentiation. Data were analyzed in triplicate and displayed as mean±SEM. All samples were analyzed by 400 μl of
media supernatant. (⁎ denotes Pb0.05 compared to day 14 basal media.) (B) CYP1A2 activity in hESC-derived hepatic cells grown for 2
weeks in high-performance media, measured by EROD activity. Basal media showed minimal activity, whereas, the high-performance
media had significant activity. Samples had no detectable levels of CYP1A2 activity prior to initiation. Data were analyzed in triplicate
and displayed as mean±SEM. (⁎ denotes Pb0.05 compared to complete media, § denotes Pb0.01 compared to complete media.) (C)
ICG uptake and release. hESCs were grown for 2 weeks in culture in high-performance media and qualitatively evaluated for their
ability to take up ICG (left column) and release it 6 h later (right column, shown at two different magnifications, 10X and 40X).
Abbreviations: ICG, indocyanine green; CYP, cytochrome P450; EROD, ethoxyresorufin O-de-ethylase.
57Expedited growth factor-mediated specification of human embryonic stem cells toward the hepatic lineagedevelopment in vivo (Hay et al., 2008b). Similar to our
protocol, Wnt3a and activin A treatments were investigated
to induce hepatic differentiation (Hay et al., 2008b). Our
system uses activin A priming to efficiently induce definitive
endoderm, without the need for Wnt3a. Following activin A
priming, the addition of Wnt3a alone was not sufficient to
induce hepatic differentiation unless it was in conjunctionwith DOH treatment (data not shown), perhaps due to the
fact that Wnt3a is downregulated after 3 days of endoderm
specification (Hay et al., 2008b). The synergistic effect of
priming the hESCs with activin A and supplementing with DOH
or DOHW induced significant hepatic differentiation com-
pared to any single component alone (data not shown) or
basal media controls. The addition of Wnt3a to DOH or ADOH
Figure 6 Representative immunofluorescent staining for ALB/CK18 in hESC-derived cells. Adherent cultures were grown for 2 weeks
and stained with classic hepatic markers. ALB/CK18 coexpression is prominent in DOH, Ad0-4DOHW, and Ad0-4DOH cultures.
Undifferentiated cells in complete and basal media were negative for ALB/CK18. The ALB/CK18-positive cells under the A0-4DOH
conditions had distinct cuboidal morphology and appear to be binucleated (confirmed at higher magnification of 63X with DAPI
counterstaining), indicative of hepatocyte-like cells. Abbreviations: ALB, albumin; CK18, cytokeratin-18. Scale Bar in all images = 150 µm.
58 R.N. Moore, P.V. Mogheprovides a system that lacks preventative factors, such as
bFGF, TGF-β, to support differentiation (Dravid et al., 2005).
To further determine the highest inducing growth factor
combinations, functional activity (albumin secretion, cellu-
lar uptake and release of indocyanine green, and inducible
cytochrome P450 activity) of the hESCs was analyzed.
Consistent data from several approaches to quantify hepatic
differentiation concluded that DOH, Ad0-4DOH, and Ad0-
4DOHW treatments were deemed the highest performing
combinations and were therefore further evaluated for their
ability to induce differentiation. The high-performance
cocktails (DOH, Ad0-4DOH, and Ad0-4DOHW) were character-
ized for their albumin and cytokeratin 18 staining and
expression profiles. Albumin is a classic hepatic marker and
often used in conjunction with CK18 to confirm coexpression.
CK18 is perhaps the most commonly found member of the
intermediate filament gene family and is indicative of
hepatocyte morphology. All high-performance media showed
ALB/CK18 staining, but the most striking staining associated
with characteristic cuboidal morphology and the presence of
double nuclei was found under the Ad0-4DOH conditions,
indicative of hepatic differentiation. Flow cytometric
analysis of undifferentiated and Ad0-4DOH-derived hESCs
showed that in the presence of high-performance growth
factors, over 70% of the cell population is ALB and CK18
positive after 4 weeks in terminal differentiation culture.
These data reveal that the directed differentiation process
largely yields cells that are hepatic in nature.
To determine whether most differentiated cells with
morphological and functional characteristics also have
genetic profiles of hepatocyte-like cells, the hESC-derived
cells were evaluated for gene expression profiles forhepatocyte-associated markers. These hepatocyte nuclear
factors are transcriptional activators for liver-specific
transcripts such as albumin and transthyretin. All high-
performance groups and EBs have higher expression of the
transcription factor, FOXA2, found in the earliest stages of
definitive endoderm, compared to complete media illus-
trating that the EB process can induce endoderm differ-
entiation similar to DOH, Ad0-4DOH, and Ad0-4DOHW. Similar
to FOXA2, transthyretin, or prealbumin, was found to be
upregulated in all high-performance media and the EB
condition. Further analysis of mid-late hepatic markers
provides evidence that EB development alone cannot
achieve hepatic differentiation on the levels associated
with the high-performance media. Mid and late hepatic
markers were evaluated and showed that alpha-1-anti-
trypsin was highly upregulated under the activin A
pretreatment conditions while hepatocyte nuclear factor-
4 and cytokeratin 18 were upregulated in all high-
performance media, indicating that definitive endoderm-
restricted cells can achieve hepatocyte-like gene expres-
sion profiles with the selected growth factor regime. The
insights gained from the gene expression profiles demon-
strate that the high-performance media are able to
upregulate mid and late hepatic markers, whereas embry-
oid body differentiation is only able to induce endoderm-
associated genes, supporting the idea that spontaneous EB
lineage restriction is an unregulated and indirect differ-
entiation process. For this reason, growth factor supple-
mentation is essential if attempting to direct hepatic
differentiation from cells isolated from EBs (Shirahashi et
al., 2004; Baharvand et al., 2006; Lavon et al., 2004;
Rambhatla et al., 2003; Schwartz et al., 2005).
59Expedited growth factor-mediated specification of human embryonic stem cells toward the hepatic lineageIn conclusion, our findings provide a simple system for
further investigation into the differentiation pathways
associated with hepatic lineage restriction. Here we describe
an efficient process for directed differentiation of hESCs
without the use of embryoid body development combined
with the addition of select exogenous growth factors. Based
on the emerging molecular biology of hESCs, the use of
molecular growth factors in conjunction with gene-targeting
approaches (for example, siRNA) may be other avenues to
further differentiate hESCs. Future studies to expand three-
dimensional hESCs may also incorporate the use of three-
dimensional scaffolds that can combine selected growth
factor supplementation within a controlled microenviron-
ment for scaling up cell numbers for clinical research
applications.
Materials and methods
Propagation of undifferentiated hESCs
Human embryonic stem cells (H1) were obtained from WiCell
Research Institute (Madison, WI) and maintained following
WiCell protocols. Briefly, cells were cultivated in gelatin-
coated, six-well plates in complete media consisting of
DMEM-F12 supplemented with 20% KnockOut Serum Replacer,
200 mM L-glutamine, beta-mercaptoethanol, nonessential
amino acids, 4 ng/ml basic fibroblast growth factor, and
0.12 ng/ml transforming growth factor-beta (TGF-β). Med-
ium was changed daily. After collagenase IV treatment for 5–
10 min at 37 °C followed by mechanical dissociation, colonies
were passaged weekly at a ratio of 1:6 on mitotically
inactivated (X-irradiated, 6500 rad) mouse embryonic
fibroblasts (MEFs).
Initiation of hESC differentiation
Directed differentiation was accomplished by culturing the
hESCs on MEFs in the presence of various growth factors over
a 2-week period. Human ES cells in complete media were
allowed to attach overnight on the MEFs and subsequently
cultured in basal media with various growth factor treat-
ments (see Fig. 1). Basal media consists of complete media
without the addition of b-FGF and TGF-β. Growth factor
combinations consisted of permutations of up to five
components added to the basal media: dexamathasone
(10−7 M); oncostatin M (10 ng/ml); hepatocyte growth factor
(20 ng/ml); (Sigma, Atlanta, GA), activin A (50 ng/ml), and
Wnt3A (100 ng/ml) (R&D Systems, Minneapolis, MN).
Colonies were allowed to grow for 1 or 2 weeks in culture
with media changed daily. As a comparison culture condition
(control), embryoid bodies were formed by placing disso-
ciated colonies in an ultralow attachment plate in the
presence of basal media for 2 weeks with media changed
every 2 days. Fig. 1 provides an illustration of the
differentiation process.
Immunocytochemistry of hepatocyte-like cells
After 1 and 2 weeks in culture with various growth factor
combinations, hESCs were stained for hepatospecific mar-kers to determine the extent of differentiation. Culture
conditions were fixed with 4% paraformaldehyde in Dulbec-
co's phosphate-buffered saline (DPBS) with Ca2+ and Mg2+ for
15 min at room temperature. Cells were then rapidly washed
three times with DPBS and permeabilized with SAP buffer
(0.5% Saponin, 1% BSA, 0.1% sodium azide) (Sigma, St. Louis,
MO) for 30 min at room temperature. After washing once
with DPBS, cells were blocked with 3% (w/v) bovine albumin
serum (BSA) for 30 min at room temperature to reduce
nonspecific antibody binding. Subsequently, primary anti-
bodies for hepatic identification were incubated overnight at
4°C with the addition of SSEA-4 as a counterstain for
pluripotency. The primary antibodies, diluted in SAP buffer,
are as follows: alpha-fetoprotein IgG1, 1:200 dilution
(Abcam, Cambridge, MA); albumin IgG2b, 2.5 μg/ml
(Abcam); cytokeratin 18 IgG1, 1:800 dilution (Abcam); and
SSEA-4 IgG3, 1:200 dilution (Millipore, Chicago, IL). Cells
were washed three times with DPBS and incubated with
isotype-matched secondary antibodies, 1:1000 dilution in
SAP buffer for 1 h at room temperature. The secondary
antibodies are as follows: AlexaFluor 488 IgG1, AlexaFluor
488 IgG2b, and AlexaFluor 594 IgG3 (Invitrogen, Carlsbad,
CA). Finally, the cells were washed four times in DPBS and
visualized using the Leica TCS.SP2 confocal microscope
system (Leica Microscope, Exton, PA).
RNA extraction and reverse
transcriptase–polymerase chain reaction analysis
Total RNA was extracted from the cell pellets using the
RNEasy kit (Qiagen, Valencia, CA) according to the manufac-
turer's instructions. The high-capacity cDNA reverse tran-
scription kit and random primers (Applied Biosystems, Foster
City, CA) were used to reverse transcribe total RNA to single-
stranded cDNA for real-time PCR. Various genes were
analyzed to determine hepatospecific markers including
alpha-fetoprotein, albumin, forkhead box A2, transthyretin,
hepatocyte nuclear factor-4, alpha-1-antitrypsin, cytoker-
atin 18, and beta-actin (SuperArray, Frederick, MD). Quanti-
tative real-time PCR was performed using the SYBR Green
PCR Master Mix (Qiagen) and the LightCycler System (Roche,
Indianapolis, IN). cDNA samples, 1 μl in a 10 μl volume
reaction, were analyzed for the gene of interest and for the
housekeeping gene, beta-actin. Data represent samples in
triplicate and displayed as mean±SEM. Statistical analysis
was completed by single-variable ANOVA followed by multi-
ple comparison testing.
Human albumin secretion by differentiated hESCs
An ELISA Quantitation kit (Bethyl Laboratories, Montgomery,
TX) was used to measure human albumin levels secreted in
culture medium. Samples from three separate cultures were
analyzed in duplicate for each condition. ELISA plates were
read at 450 nm and the resulting data analyzed with a four-
parameter curve-fitting computer program (KaleidaGraph).
The absorbance of the basal medium was subtracted from
each sample absorbance, and albumin concentration was
determined from the standard curve. The final absorbance of
the test samples was obtained after subtracting the zero
absorbance and used to determine albumin concentrations
60 R.N. Moore, P.V. Moghesecreted into the media. Data represent samples in triplicate
and displayed as mean±SEM. Statistical analysis was com-
pleted by ANOVA single factor analysis.EROD assay
To determine the metabolic activity of the hESC-derived
hepatic-like cells, an ethoxyresorufin O-de-ethylase assay
was performed. Cytochrome P450 enzymes metabolize
xenobiotic compounds with which they come in contact.
After culturing the hESCs in high-performance media for 2
weeks, the EROD assay assessed the CYP1A2 activity. Briefly,
cells were induced with 5 μM methylchloranthrene (Sigma)
in respective media and cultured for 24 h. Cells were
washed with PBS and cultured with 5 μM ethoxyresorufin
(Sigma) for 2 h to initiate the EROD assay. The reaction was
stopped with 20 mM NaOH and the supernatant was
collected and measured on a fluorescence plate reader at
355 nm excitation and 581 nm emission. A standard curve of
pure resorufin was used to calculate the activity of CYP1A2
in picomoles of resorufin formed per minute per million
cells.Cellular uptake and release of indocyanine green
Indocyanine green (ICG) is an inorganic anion that is used to
evaluate liver function because it is nontoxic and eliminated
exclusively by hepatocytes (Yamada et al., 2002). Briefly,
hESC-derived hepatic-like cells were cultured for 2 weeks in
high-performance media and incubated with diluted ICG
(Sigma) in media (1 mg/ml) for 30 min at 37 °C. Cultures
were washed and imaged with transmitted light to
determine the amount of ICG uptake, indicated by green
stain. Cells were cultured for an additional 6 h in culture
media, washed, and imaged again to document release of
cellular ICG stain.Fluorescence-activated cell sorting analysis
To determine the percentage population positive for albumin
and CK18, cells were processed and analyzed by fluorescent-
activated cell sorting (FACS) (Becton Dickinson, Franklin
Lakes, NJ). The highest performance media (A4DOH) were
grown for up to 4 weeks and analyzed every other week for
albumin and CK18 expression. Briefly, single-cell suspensions
were used with fluorescent-conjugated antibodies against
human albumin and cytokeratin 18. Cells were fixed with 1%
paraformaldehyde (15 min, on ice), washed twice, permea-
bilized with SAP buffer (30 min, on ice), washed twice,
blocked with 3% BSA (30 min, on ice), and washed again
twice. Cell identification was confirmed by staining with
primary antibodies against human albumin (R&D Systems),
0.5 μg/ml, and human cytokeratin 18 (Millipore), dilution
1:100, for 1 h on ice. Cells were washed twice and labeled
with AlexaFluor goat anti mouse IgG (H+L) 488 (Invitrogen)
for 1 h on ice, 1:1000 dilution. Finally, cells were washed
three times with PBS and analyzed with CellQuest software
(BD Biosciences). MEFs alone were run with each experiment
as a negative control.Acknowledgments
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